New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy

Research Reveals Reduction in Hospitalization Rates, Length of Stay and Health Care Costs When Treating OIC with FDA-Approved Prescription Medications
LAVAL, QC, March 24, 2022 /PRNewswire/ --... | March 24, 2022

Related Keywords

New Jersey ,United States ,Canada ,Canadian ,Lainie Keller ,Frank Peacock ,Arthur Shannon ,Bausch Health Companies Inc ,Research At Baylor College Of Medicine ,Health Care Costs When Treating ,Emergency Department ,Linkedin ,Research Reveals Reduction In Hospitalization ,Twitter ,Drug Administration ,Salix Pharmaceuticals ,Exchange Commission ,Prnewswire Bausch Health Companies Inc ,Bausch Health ,Research Reveals Reduction ,Hospitalization Rates ,Approved Prescription ,Health Companies ,Baylor College ,Induced Constipation ,Cost Impact ,Approved Medications ,Child Pugh Class ,Prescribing Information ,Canadian Securities Administrators ,Bausch Health Companies Inc Stock Exchange ,News ,Information ,Press Release ,Research ,Eveals ,Reduction ,N ,Hospitalization ,Length ,F ,Stay ,End ,Health ,Mare ,Costs ,When ,Reating ,Dic ,Ith ,Prescription ,Arch ,022 Bhc Ca0717341071 ,